Comparison of adverse events during capecitabine versus 5-fluorouracil/oxaliplatin adjuvantchemotherapy for stage II/III colon cancer: A population based analysis.

被引：0
|
作者：
Pabani, Aliyah
Mazurek, Matthew
Cheung, Winson Y.
Spratlin, Jennifer L.
Hiller, Julie A. Price
Standeven, Leah Jean
Mulder, Karen E.
Ghosh, Sunita
Ho, Maria Yi
机构：
[1] Univ Alberta, Edmonton, AB, Canada
[2] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[3] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[4] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e14663
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14663
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients
    Chen, Hong-Hwa
    Chen, William Tzu-Liang
    Lee, Hsin-Chung
    Lin, Jen-Kou
    Fang, Chuan-Yin
    Chou, Yenn-Hwei
    Lin, Peng-Chan
    Lin, Bo-Wen
    Huang, Chi-Chou
    Yeh, Chung-Hung
    Hsu, Hsi-Hsien
    Chen, Hung-Chang
    Ting, Wen-Chien
    Yang, Ming-Chin
    Tan, Elise Chia-Hui
    QUALITY OF LIFE RESEARCH, 2015, 24 (02) : 473 - 484
  • [22] Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients
    Hong-Hwa Chen
    William Tzu-Liang Chen
    Hsin-Chung Lee
    Jen-Kou Lin
    Chuan-Yin Fang
    Yenn-Hwei Chou
    Peng-Chan Lin
    Bo-Wen Lin
    Chi-Chou Huang
    Chung-Hung Yeh
    Hsi-Hsien Hsu
    Hung-Chang Chen
    Wen-Chien Ting
    Ming-Chin Yang
    Elise Chia-Hui Tan
    Quality of Life Research, 2015, 24 : 473 - 484
  • [23] Phase III study of 5-fluorouracil/leucovorin plus oxaliplatin versus capecitabine plus oxaliplatin as first line therapy in patients with advanced colorectal cancer (ACRC)
    Porschen, R
    Arkenau, T
    Kubicka, S
    Schmoll, HJ
    Seufferlein, T
    Graeven, U
    Grothey, A
    GASTROENTEROLOGY, 2005, 128 (04) : A438 - A438
  • [24] Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).
    Schmoll, Hans-Joachim
    Tabernero, Josep
    Maroun, Jean Alfred
    De Braud, Filippo G.
    Price, Timothy Jay
    Van Cutsem, Eric
    Hill, Mark
    Hoersch, Silke
    Rittweger, Karen
    Haller, Daniel G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [25] Erratum: Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer
    A Sobrero
    G Frassineti
    A Falcone
    L Dogliotti
    R Rosso
    F Di Costanzo
    P Bruzzi
    British Journal of Cancer, 2005, 93 : 733 - 733
  • [26] Patients With Locally Advanced and Metastatic Colorectal Cancer Treated With Capecitabine Versus 5-Fluorouracil as Monotherapy or Combination Therapy With Oxaliplatin: A Cost Comparison
    Chu, Edward
    Schulman, Kathy L.
    McKenna, Edward F., Jr.
    Cartwright, Thomas
    CLINICAL COLORECTAL CANCER, 2010, 9 (04) : 229 - 237
  • [27] Infusiorial 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis.
    Arkenau, HT
    Schmoll, H
    Kubicka, S
    Kretzschmar, A
    Freier, W
    Seufferlein, T
    Graeven, U
    Grothey, A
    Hinke, A
    Porschen, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 247S - 247S
  • [28] Patterns of use and outcomes with irinotecan and oxaliplatin in the treatment of 5-fluorouracil (5-FU) refractory metastatic colorectal cancer: An Australian population based analysis.
    Damianovich, D.
    Adena, M.
    Tebbutt, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 178S - 178S
  • [29] Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
    Tomas Buchler
    Tomas Pavlik
    Bohuslav Melichar
    Zbynek Bortlicek
    Zuzana Usiakova
    Ladislav Dusek
    Igor Kiss
    Milan Kohoutek
    Vera Benesova
    Rostislav Vyzula
    Jitka Abrahamova
    Radka Obermannova
    BMC Cancer, 14
  • [30] Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX)
    Jeong Eun Kim
    Yong Sang Hong
    Hwa Jung Kim
    Kyu-pyo Kim
    Sun Young Kim
    Seok-Byung Lim
    In Ja Park
    Chan Wook Kim
    Yong Sik Yoon
    Chang Sik Yu
    Jin Cheon Kim
    Ji Hun Kim
    Tae Won Kim
    Annals of Surgical Oncology, 2017, 24 : 1289 - 1294
12345